The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial
•42 patients received a 500 mg/day quercetin and 42 others took a 500 mg/day placebo for 12 w.•Quercetin could significantly reduce ferritin and other serum iron factors (P > 0.05).•Quercetin significantly reduced hs-CRP (P = 0.046), but not TNF-α (p = 0.310).•According to our results, quercetin...
Gespeichert in:
| Veröffentlicht in: | Complementary therapies in medicine 2019-10, Vol.46, p.24-28 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 28 |
|---|---|
| container_issue | |
| container_start_page | 24 |
| container_title | Complementary therapies in medicine |
| container_volume | 46 |
| creator | Sajadi Hezaveh, Zohreh Azarkeivan, Azita Janani, Leila Hosseini, Sharieh Shidfar, Farzad |
| description | •42 patients received a 500 mg/day quercetin and 42 others took a 500 mg/day placebo for 12 w.•Quercetin could significantly reduce ferritin and other serum iron factors (P > 0.05).•Quercetin significantly reduced hs-CRP (P = 0.046), but not TNF-α (p = 0.310).•According to our results, quercetin may be useful to reduce ferritin and inflammation in thalassemia major patients.
The aim of this study was to determine whether quercetin can reduce iron overload and inflammation in thalassemic patients.
Eighty four patients were recruited to this study and randomly assigned to two groups: 42 patients received a 500 mg/day quercetin tablet and 42 others took a 500 mg/day starch placebo for 12 weeks. Demographic, anthropometric and biochemical evaluation were performed.
ANCOVA analysis revealed that compared to the control group, quercetin could reduce high sensitivity C-reactive protein (hs-CRP) (P = 0.046), iron (p = 0.036), ferritin (p = 0.043), and transferrin saturation (TS) (p = 0.008) and increase transferrin (p = 0.045) significantly, but it had no significant effect on total iron binding capacity (TIBC) (p = 0.734) and tumor necrosis factor α (TNF-α) (p = 0.310).
Quercetin could ameliorate the iron status in thalassemia major, but its effect on inflammation is indistinctive. |
| doi_str_mv | 10.1016/j.ctim.2019.02.017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2290835001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0965229919300494</els_id><sourcerecordid>2287409187</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-d3b70352c19e37b6b3459fdc4f9bccd92e2d82712436ffa795de9a9e7475feff3</originalsourceid><addsrcrecordid>eNp9kc-K1TAYxYMozvXqC7iQgBs3rfnTNo24GQb_wYCbcR3S5AuTkjTXpB3QtU_kg_hMptzRhQs3CeQ755Dv_BB6TklLCR1ez61ZfWwZobIlrCVUPEAHOgreDHLgD9GByKFvGJPyAj0pZSaESC74Y3TBaU8lG_kB_bi5BQzOgVlxcvjrBtnA6hecFuxzPdId5JC0xXqx2C8u6Bj16vfxgn_9bNZbHXQpEL3GUc8p41Mdw7KWN_gS27RNAZop-OrONSJF_x0sNvXBGx3wmr0OT9Ejp0OBZ_f3EX15_-7m6mNz_fnDp6vL68bwsVsbyydBeM8MlcDFNEy866WzpnNyMsZKBsyOTFDW8cE5LWRvQWoJohO9qzvyI3p1zj3lVDctq4q-GAhBL5C2ompVZOQ9IbRKX_4jndOWl_q7qhpFR-Re9BGxs8rkVEoGp07ZR52_KUrUzkjNamekdkaKMFUZVdOL--htimD_Wv5AqYK3ZwHULu48ZFVMbdSA9blyUjb5_-X_BiZfpSo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2287409187</pqid></control><display><type>article</type><title>The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Sajadi Hezaveh, Zohreh ; Azarkeivan, Azita ; Janani, Leila ; Hosseini, Sharieh ; Shidfar, Farzad</creator><creatorcontrib>Sajadi Hezaveh, Zohreh ; Azarkeivan, Azita ; Janani, Leila ; Hosseini, Sharieh ; Shidfar, Farzad</creatorcontrib><description>•42 patients received a 500 mg/day quercetin and 42 others took a 500 mg/day placebo for 12 w.•Quercetin could significantly reduce ferritin and other serum iron factors (P > 0.05).•Quercetin significantly reduced hs-CRP (P = 0.046), but not TNF-α (p = 0.310).•According to our results, quercetin may be useful to reduce ferritin and inflammation in thalassemia major patients.
The aim of this study was to determine whether quercetin can reduce iron overload and inflammation in thalassemic patients.
Eighty four patients were recruited to this study and randomly assigned to two groups: 42 patients received a 500 mg/day quercetin tablet and 42 others took a 500 mg/day starch placebo for 12 weeks. Demographic, anthropometric and biochemical evaluation were performed.
ANCOVA analysis revealed that compared to the control group, quercetin could reduce high sensitivity C-reactive protein (hs-CRP) (P = 0.046), iron (p = 0.036), ferritin (p = 0.043), and transferrin saturation (TS) (p = 0.008) and increase transferrin (p = 0.045) significantly, but it had no significant effect on total iron binding capacity (TIBC) (p = 0.734) and tumor necrosis factor α (TNF-α) (p = 0.310).
Quercetin could ameliorate the iron status in thalassemia major, but its effect on inflammation is indistinctive.</description><identifier>ISSN: 0965-2299</identifier><identifier>EISSN: 1873-6963</identifier><identifier>DOI: 10.1016/j.ctim.2019.02.017</identifier><identifier>PMID: 31519283</identifier><language>eng</language><publisher>Scotland: Elsevier Ltd</publisher><subject>Adult ; Age ; Anthropometry ; beta-Thalassemia - drug therapy ; beta-Thalassemia - metabolism ; Binding sites ; Blood transfusions ; C-reactive protein ; C-Reactive Protein - metabolism ; Chelation therapy ; Clinical trial ; Clinical trials ; Demographics ; Diabetes ; Diet ; Disease ; Double-Blind Method ; Double-blind studies ; Evidence-based medicine ; Female ; Ferritin ; Ferritins - metabolism ; Hemoglobin ; Humans ; Inflammation ; Inflammation - chemically induced ; Inflammation - drug therapy ; Inflammation - metabolism ; Iron ; Iron - adverse effects ; Iron - therapeutic use ; Iron Overload - chemically induced ; Iron Overload - drug therapy ; Iron Overload - metabolism ; Liver ; Male ; Metabolism ; Pediatrics ; Quercetin ; Quercetin - therapeutic use ; Research centers ; Starch ; Thalassemia ; Thalassemia major ; Transferrin ; Transferrin - metabolism ; Transferrins ; Tumor necrosis factor-α</subject><ispartof>Complementary therapies in medicine, 2019-10, Vol.46, p.24-28</ispartof><rights>2019 Elsevier Ltd</rights><rights>Copyright © 2019 Elsevier Ltd. All rights reserved.</rights><rights>2019. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-d3b70352c19e37b6b3459fdc4f9bccd92e2d82712436ffa795de9a9e7475feff3</citedby><cites>FETCH-LOGICAL-c384t-d3b70352c19e37b6b3459fdc4f9bccd92e2d82712436ffa795de9a9e7475feff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0965229919300494$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31519283$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sajadi Hezaveh, Zohreh</creatorcontrib><creatorcontrib>Azarkeivan, Azita</creatorcontrib><creatorcontrib>Janani, Leila</creatorcontrib><creatorcontrib>Hosseini, Sharieh</creatorcontrib><creatorcontrib>Shidfar, Farzad</creatorcontrib><title>The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial</title><title>Complementary therapies in medicine</title><addtitle>Complement Ther Med</addtitle><description>•42 patients received a 500 mg/day quercetin and 42 others took a 500 mg/day placebo for 12 w.•Quercetin could significantly reduce ferritin and other serum iron factors (P > 0.05).•Quercetin significantly reduced hs-CRP (P = 0.046), but not TNF-α (p = 0.310).•According to our results, quercetin may be useful to reduce ferritin and inflammation in thalassemia major patients.
The aim of this study was to determine whether quercetin can reduce iron overload and inflammation in thalassemic patients.
Eighty four patients were recruited to this study and randomly assigned to two groups: 42 patients received a 500 mg/day quercetin tablet and 42 others took a 500 mg/day starch placebo for 12 weeks. Demographic, anthropometric and biochemical evaluation were performed.
ANCOVA analysis revealed that compared to the control group, quercetin could reduce high sensitivity C-reactive protein (hs-CRP) (P = 0.046), iron (p = 0.036), ferritin (p = 0.043), and transferrin saturation (TS) (p = 0.008) and increase transferrin (p = 0.045) significantly, but it had no significant effect on total iron binding capacity (TIBC) (p = 0.734) and tumor necrosis factor α (TNF-α) (p = 0.310).
Quercetin could ameliorate the iron status in thalassemia major, but its effect on inflammation is indistinctive.</description><subject>Adult</subject><subject>Age</subject><subject>Anthropometry</subject><subject>beta-Thalassemia - drug therapy</subject><subject>beta-Thalassemia - metabolism</subject><subject>Binding sites</subject><subject>Blood transfusions</subject><subject>C-reactive protein</subject><subject>C-Reactive Protein - metabolism</subject><subject>Chelation therapy</subject><subject>Clinical trial</subject><subject>Clinical trials</subject><subject>Demographics</subject><subject>Diabetes</subject><subject>Diet</subject><subject>Disease</subject><subject>Double-Blind Method</subject><subject>Double-blind studies</subject><subject>Evidence-based medicine</subject><subject>Female</subject><subject>Ferritin</subject><subject>Ferritins - metabolism</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation - chemically induced</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - metabolism</subject><subject>Iron</subject><subject>Iron - adverse effects</subject><subject>Iron - therapeutic use</subject><subject>Iron Overload - chemically induced</subject><subject>Iron Overload - drug therapy</subject><subject>Iron Overload - metabolism</subject><subject>Liver</subject><subject>Male</subject><subject>Metabolism</subject><subject>Pediatrics</subject><subject>Quercetin</subject><subject>Quercetin - therapeutic use</subject><subject>Research centers</subject><subject>Starch</subject><subject>Thalassemia</subject><subject>Thalassemia major</subject><subject>Transferrin</subject><subject>Transferrin - metabolism</subject><subject>Transferrins</subject><subject>Tumor necrosis factor-α</subject><issn>0965-2299</issn><issn>1873-6963</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kc-K1TAYxYMozvXqC7iQgBs3rfnTNo24GQb_wYCbcR3S5AuTkjTXpB3QtU_kg_hMptzRhQs3CeQ755Dv_BB6TklLCR1ez61ZfWwZobIlrCVUPEAHOgreDHLgD9GByKFvGJPyAj0pZSaESC74Y3TBaU8lG_kB_bi5BQzOgVlxcvjrBtnA6hecFuxzPdId5JC0xXqx2C8u6Bj16vfxgn_9bNZbHXQpEL3GUc8p41Mdw7KWN_gS27RNAZop-OrONSJF_x0sNvXBGx3wmr0OT9Ejp0OBZ_f3EX15_-7m6mNz_fnDp6vL68bwsVsbyydBeM8MlcDFNEy866WzpnNyMsZKBsyOTFDW8cE5LWRvQWoJohO9qzvyI3p1zj3lVDctq4q-GAhBL5C2ompVZOQ9IbRKX_4jndOWl_q7qhpFR-Re9BGxs8rkVEoGp07ZR52_KUrUzkjNamekdkaKMFUZVdOL--htimD_Wv5AqYK3ZwHULu48ZFVMbdSA9blyUjb5_-X_BiZfpSo</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Sajadi Hezaveh, Zohreh</creator><creator>Azarkeivan, Azita</creator><creator>Janani, Leila</creator><creator>Hosseini, Sharieh</creator><creator>Shidfar, Farzad</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201910</creationdate><title>The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial</title><author>Sajadi Hezaveh, Zohreh ; Azarkeivan, Azita ; Janani, Leila ; Hosseini, Sharieh ; Shidfar, Farzad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-d3b70352c19e37b6b3459fdc4f9bccd92e2d82712436ffa795de9a9e7475feff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Age</topic><topic>Anthropometry</topic><topic>beta-Thalassemia - drug therapy</topic><topic>beta-Thalassemia - metabolism</topic><topic>Binding sites</topic><topic>Blood transfusions</topic><topic>C-reactive protein</topic><topic>C-Reactive Protein - metabolism</topic><topic>Chelation therapy</topic><topic>Clinical trial</topic><topic>Clinical trials</topic><topic>Demographics</topic><topic>Diabetes</topic><topic>Diet</topic><topic>Disease</topic><topic>Double-Blind Method</topic><topic>Double-blind studies</topic><topic>Evidence-based medicine</topic><topic>Female</topic><topic>Ferritin</topic><topic>Ferritins - metabolism</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation - chemically induced</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - metabolism</topic><topic>Iron</topic><topic>Iron - adverse effects</topic><topic>Iron - therapeutic use</topic><topic>Iron Overload - chemically induced</topic><topic>Iron Overload - drug therapy</topic><topic>Iron Overload - metabolism</topic><topic>Liver</topic><topic>Male</topic><topic>Metabolism</topic><topic>Pediatrics</topic><topic>Quercetin</topic><topic>Quercetin - therapeutic use</topic><topic>Research centers</topic><topic>Starch</topic><topic>Thalassemia</topic><topic>Thalassemia major</topic><topic>Transferrin</topic><topic>Transferrin - metabolism</topic><topic>Transferrins</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sajadi Hezaveh, Zohreh</creatorcontrib><creatorcontrib>Azarkeivan, Azita</creatorcontrib><creatorcontrib>Janani, Leila</creatorcontrib><creatorcontrib>Hosseini, Sharieh</creatorcontrib><creatorcontrib>Shidfar, Farzad</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Complementary therapies in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sajadi Hezaveh, Zohreh</au><au>Azarkeivan, Azita</au><au>Janani, Leila</au><au>Hosseini, Sharieh</au><au>Shidfar, Farzad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial</atitle><jtitle>Complementary therapies in medicine</jtitle><addtitle>Complement Ther Med</addtitle><date>2019-10</date><risdate>2019</risdate><volume>46</volume><spage>24</spage><epage>28</epage><pages>24-28</pages><issn>0965-2299</issn><eissn>1873-6963</eissn><abstract>•42 patients received a 500 mg/day quercetin and 42 others took a 500 mg/day placebo for 12 w.•Quercetin could significantly reduce ferritin and other serum iron factors (P > 0.05).•Quercetin significantly reduced hs-CRP (P = 0.046), but not TNF-α (p = 0.310).•According to our results, quercetin may be useful to reduce ferritin and inflammation in thalassemia major patients.
The aim of this study was to determine whether quercetin can reduce iron overload and inflammation in thalassemic patients.
Eighty four patients were recruited to this study and randomly assigned to two groups: 42 patients received a 500 mg/day quercetin tablet and 42 others took a 500 mg/day starch placebo for 12 weeks. Demographic, anthropometric and biochemical evaluation were performed.
ANCOVA analysis revealed that compared to the control group, quercetin could reduce high sensitivity C-reactive protein (hs-CRP) (P = 0.046), iron (p = 0.036), ferritin (p = 0.043), and transferrin saturation (TS) (p = 0.008) and increase transferrin (p = 0.045) significantly, but it had no significant effect on total iron binding capacity (TIBC) (p = 0.734) and tumor necrosis factor α (TNF-α) (p = 0.310).
Quercetin could ameliorate the iron status in thalassemia major, but its effect on inflammation is indistinctive.</abstract><cop>Scotland</cop><pub>Elsevier Ltd</pub><pmid>31519283</pmid><doi>10.1016/j.ctim.2019.02.017</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0965-2299 |
| ispartof | Complementary therapies in medicine, 2019-10, Vol.46, p.24-28 |
| issn | 0965-2299 1873-6963 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2290835001 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Age Anthropometry beta-Thalassemia - drug therapy beta-Thalassemia - metabolism Binding sites Blood transfusions C-reactive protein C-Reactive Protein - metabolism Chelation therapy Clinical trial Clinical trials Demographics Diabetes Diet Disease Double-Blind Method Double-blind studies Evidence-based medicine Female Ferritin Ferritins - metabolism Hemoglobin Humans Inflammation Inflammation - chemically induced Inflammation - drug therapy Inflammation - metabolism Iron Iron - adverse effects Iron - therapeutic use Iron Overload - chemically induced Iron Overload - drug therapy Iron Overload - metabolism Liver Male Metabolism Pediatrics Quercetin Quercetin - therapeutic use Research centers Starch Thalassemia Thalassemia major Transferrin Transferrin - metabolism Transferrins Tumor necrosis factor-α |
| title | The effect of quercetin on iron overload and inflammation in β-thalassemia major patients: A double-blind randomized clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T23%3A20%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20quercetin%20on%20iron%20overload%20and%20inflammation%20in%20%CE%B2-thalassemia%20major%20patients:%20A%20double-blind%20randomized%20clinical%20trial&rft.jtitle=Complementary%20therapies%20in%20medicine&rft.au=Sajadi%20Hezaveh,%20Zohreh&rft.date=2019-10&rft.volume=46&rft.spage=24&rft.epage=28&rft.pages=24-28&rft.issn=0965-2299&rft.eissn=1873-6963&rft_id=info:doi/10.1016/j.ctim.2019.02.017&rft_dat=%3Cproquest_cross%3E2287409187%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2287409187&rft_id=info:pmid/31519283&rft_els_id=S0965229919300494&rfr_iscdi=true |